Moyamoya disease: a review of histopathology, biochemistry, and genetics

被引:68
作者
Weinberg, David G.
Arnaout, Omar M.
Rahme, Rudy J.
Aoun, Salah G.
Batjer, H. Hunt
Bendok, Bernard R. [1 ]
机构
[1] Northwestern Univ, Dept Neurol Surg, Feinberg Sch Med, Chicago, IL 60611 USA
关键词
moyamoya disease; histopathology; biochemistry; genetics; FIBROBLAST-GROWTH-FACTOR; INTRACRANIAL MAJOR ARTERIES; CEREBROSPINAL-FLUID; SPONTANEOUS OCCLUSION; FACTOR-BETA; EXPRESSION; CHILDREN; LINKAGE; CELLS; CHROMOSOME-6;
D O I
10.3171/2011.3.FOCUS1151
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Object. Moyamoya disease (MMD) is a rare cerebrovascular disorder involving stenosis of the major vessels of the circle of Willis and proximal portions of its principal branches. Despite concerted investigation, the pathophysiology of the disorder has not been fully elucidated. Currently, the major proteins believed to play an active role in the pathogenesis include vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), hepatocyte growth factor (HGF), transforming growth factor-beta 1 (TGF beta 1), and granulocyte colony-stimulating factor (G-CSF). In terms of the genetics, recent literature suggests a low penetrance autosomal dominant or polygenic mode of transmission involving chromosomes 3, 6, 8, 12, and 17 for familial MMD. This review summarizes the current knowledge on the histopathology, pathophysiology and genetics of MMD. Methods. A PubMed/Medline systematic study of the literature was performed, from which 45 articles regarding MMD pathophysiology were identified and analyzed. Conclusions. Moyamoya disease is characterized by the intimal thickening and media attenuation of the proximal vessels of the circle of Willis as well as the development of an aberrant distal vascular network. The primary proteins that are currently implicated in the pathophysiology of MMD include VEGF, bFGF, HGF, TGFb1, and G-CSF. Furthermore, the current literature on familial MMD has pointed to a low penetrance autosomal dominant or polygenic mode of transmittance at loci on chromosomes 3, 6, 8, 12, and 17. (DOI: 10.3171/2011.3.FOCUS1151)
引用
收藏
页数:6
相关论文
共 43 条
[1]   Pathophysiology and genetic factors in moyamoya disease [J].
Achrol, Achal S. ;
Guzman, Raphael ;
Lee, Marco ;
Steinberg, Gary K. .
NEUROSURGICAL FOCUS, 2009, 26 (04)
[2]   Prothrombotic disorders in children with Moyamoya syndrome [J].
Bonduel, M ;
Hepner, M ;
Sciuccati, G ;
Torres, AF ;
Tenembaum, S .
STROKE, 2001, 32 (08) :1786-1790
[3]   Moyamoya disease: a summary [J].
Burke, Gordon M. ;
Burke, Allan M. ;
Sherma, Arun K. ;
Hurley, Michael C. ;
Batjer, H. Hunt ;
Bendok, Bernard R. .
NEUROSURGICAL FOCUS, 2009, 26 (04)
[4]   HUMAN TRANSFORMING GROWTH FACTOR-BETA COMPLEMENTARY-DNA SEQUENCE AND EXPRESSION IN NORMAL AND TRANSFORMED-CELLS [J].
DERYNCK, R ;
JARRETT, JA ;
CHEN, EY ;
EATON, DH ;
BELL, JR ;
ASSOIAN, RK ;
ROBERTS, AB ;
SPORN, MB ;
GOEDDEL, DV .
NATURE, 1985, 316 (6030) :701-705
[5]   Increased expression of serum matrix metalloproteinase-9 in patients with moyamoya disease [J].
Fujimura, Miki ;
Watanabe, Mika ;
Narisawa, Ayumi ;
Shimizu, Hiroaki ;
Tominaga, Teiji .
SURGICAL NEUROLOGY, 2009, 72 (05) :476-480
[6]   Moyamoya disease [J].
Fukui, M ;
Kono, S ;
Sueishi, K ;
Ikezaki, K .
NEUROPATHOLOGY, 2000, 20 :S61-S64
[7]   Current state of study on Moyamoya disease in Japan [J].
Fukui, M .
SURGICAL NEUROLOGY, 1997, 47 (02) :138-143
[8]  
Gannon G, 2002, CANCER RES, V62, P603
[9]   Ten-year experience of 44 patients with moyamoya disease from a single institution [J].
Garg, Anil Kumar ;
Suri, Ashish ;
Sharma, Bhawani Shankar .
JOURNAL OF CLINICAL NEUROSCIENCE, 2010, 17 (04) :460-463
[10]  
Gohda Eiichi, 2002, Nihon Yakurigaku Zasshi, V119, P287